Our Lab has studied for several years the interactions between viruses and the immune system. Our main interests comprehend:
Differential Diagnosis of Interstitial Allograft Rejection and BKV Nephropathy by T-cell Receptor Sequencing.
Stervbo U, Nienen M, Hecht J, Viebahn R, Amann K, Westhoff TH and Babel N.
(2020) Transplantation. 104, e107-e108; doi: https://doi.org/10.1097/TP.0000000000003054
BKV, CMV, and EBV Interactions and their Effect on Graft Function One Year Post-Renal Transplantation: Results from a Large Multi-Centre Study.
Blazquez-Navarro A, Dang-Heine C, Wittenbrink N, Bauer C, Wolk K, Sabat R, Westhoff TH, Sawitzki B, Reinke P, Thomusch O, Hugo C, Or-Guil M and Babel N.
(2018) EBioMedicine. 34, 113-121; doi: https://doi.org/10.1016/j.ebiom.2018.07.017
Differential T cell response against BK virus regulatory and structural antigens: A viral dynamics modelling approach.
Blazquez-Navarro A, Schachtner T, Stervbo U, Sefrin A, Stein M, Westhoff TH, Reinke P, Klipp E, Babel N, Neumann AU and Or-Guil M.
(2018) PLoS Comput Biol. 14, e1005998; doi: https://doi.org/e1005998
A revised strategy for monitoring BKV-specific cellular immunity in kidney transplant patients.
Weist BJ, Wehler P, El Ahmad L, Schmueck-Henneresse M, Millward JM, Nienen M, Neumann AU, Reinke P and Babel N.
(2015) Kidney Int. 88, 1293-1303; doi: https://doi.org/10.1038/ki.2015.215
Different risk factor profiles distinguish early-onset from late-onset BKV-replication.
Schachtner T, Babel N and Reinke P.
(2015) Transpl Int. 28, 1081-91; doi: https://doi.org/10.1111/tri.12601
Inflammatory activation and recovering BKV-specific immunity correlate with self-limited BKV replication after renal transplantation.
Schachtner T, Stein M, Sefrin A, Babel N and Reinke P.
(2014) Transpl Int. 27, 290-301; doi: https://doi.org/10.1111/tri.12251
The genetic predisposition of natural killer cell to BK virus-associated nephropathy in renal transplant patients.
Trydzenskaya H, Juerchott K, Lachmann N, Kotsch K, Kunert K, Weist B, Schönemann C, Schindler R, Nickel P, Melzig MF, Hugo C, Thomusch O, Neumann AU, Reinke P and Babel N.
(2013) Kidney Int. 84, 359-65; doi: https://doi.org/10.1038/ki.2013.59
Mannose-binding lectin deficiency is not associated with increased risk for polyomavirus nephropathy.
Liman P, Babel N, Schachtner T, Unterwalder N, König J, Hofmann J, Reinke P and Nickel P.
(2012) Transpl Immunol. 26, 123-7; doi: https://doi.org/10.1016/j.trim.2011.12.004
Novel approach for improved assessment of phenotypic and functional characteristics of BKV-specific T-cell immunity.
Trydzenskaya H, Sattler A, Müller K, Schachtner T, Dang-Heine C, Friedrich P, Nickel P, Hoerstrup J, Schindler R, Thiel A, Melzig MF, Reinke P and Babel N.
(2011) Transplantation. 92, 1269-77; doi: https://doi.org/10.1097/TP.0b013e318234e0e5
BK polyomavirus infection and nephropathy: the virus-immune system interplay.
Babel N, Volk HD and Reinke P.
(2011) Nat Rev Nephrol. 7, 399-406; doi: https://doi.org/10.1038/nrneph.2011.59
BK-VP3 as a new target of cellular immunity in BK virus infection.
Mueller K, Schachtner T, Sattler A, Meier S, Friedrich P, Trydzenskaya H, Hinrichs C, Trappe R, Thiel A, Reinke P and Babel N.
(2011) Transplantation. 91, 100-7; doi: https://doi.org/
Sustained BK viruria as an early marker for the development of BKV-associated nephropathy: analysis of 4128 urine and serum samples.
Babel N, Fendt J, Karaivanov S, Bold G, Arnold S, Sefrin A, Lieske E, Hoffzimmer M, Dziubianau M, Bethke N, Meisel C, Grütz G and Reinke P.
(2009) Transplantation. 88, 89-95; doi: https://doi.org/10.1097/TP.0b013e3181aa8f62
BKV Clearance Time Correlates With Exhaustion State and T-Cell Receptor Repertoire Shape of BKV-Specific T-Cells in Renal Transplant Patients.
Stervbo U, Nienen M, Weist BJD, Kuchenbecker L, Hecht J, Wehler P, Westhoff TH, Reinke P and Babel N.
(2019) Front Immunol. 10, 767; doi: https://doi.org/767
Interactions of TTV with BKV, CMV, EBV, and HHV-6A and their impact on post-transplant graft function in kidney transplant recipients.
Rosiewicz KS, Blazquez-Navarro A, Kaliszczyk S, Bauer C, Or-Guil M, Viebahn R, Zgoura P, Reinke P, Roch T, Hugo C, Westhoff T, Thieme C, Stervbo U and Babel N.
(2024) Front Transplant. 3, 1393838; doi: https://doi.org/1393838
High incidence and viral load of HHV-6A in a multi-centre kidney transplant cohort.
Blazquez-Navarro A, Roch T, Wehler P, Kaliszczyk S, Bauer C, Thieme C, Rosiewicz KS, Stervbo U, Anft M, Reinke P, Hugo C, Zgoura P, Viebahn R, Westhoff T, Or-Guil M and Babel N.
(2023) Front Transplant. 2, 1188535; doi: https://doi.org/1188535
BKV, CMV, and EBV Interactions and their Effect on Graft Function One Year Post-Renal Transplantation: Results from a Large Multi-Centre Study.
Blazquez-Navarro A, Dang-Heine C, Wittenbrink N, Bauer C, Wolk K, Sabat R, Westhoff TH, Sawitzki B, Reinke P, Thomusch O, Hugo C, Or-Guil M and Babel N.
(2018) EBioMedicine. 34, 113-121; doi: https://doi.org/10.1016/j.ebiom.2018.07.017
Effects of aging on human leukocytes (part II): immunophenotyping of adaptive immune B and T cell subsets.
Stervbo U, Bozzetti C, Baron U, Jürchott K, Meier S, Mälzer JN, Nienen M, Olek S, Rachwalik D, Schulz AR, Neumann A, Babel N, Grützkau A and Thiel A.
(2015) Age (Dordr). 37, 93; doi: https://doi.org/93
Different risk factor profiles distinguish early-onset from late-onset BKV-replication.
Schachtner T, Babel N and Reinke P.
(2015) Transpl Int. 28, 1081-91; doi: https://doi.org/10.1111/tri.12601
Peripheral blood-derived virus-specific memory stem T cells mature to functional effector memory subsets with self-renewal potency.
Schmueck-Henneresse M, Sharaf R, Vogt K, Weist BJ, Landwehr-Kenzel S, Fuehrer H, Jurisch A, Babel N, Rooney CM, Reinke P and Volk HD.
(2015) J Immunol. 194, 5559-67; doi: https://doi.org/10.4049/jimmunol.1402090
High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function.
Nickel P, Bold G, Presber F, Biti D, Babel N, Kreutzer S, Pratschke J, Schönemann C, Kern F, Volk HD and Reinke P.
(2009) Transpl Immunol. 20, 238-42; doi: https://doi.org/10.1016/j.trim.2008.11.002
Clonotype analysis of cytomegalovirus-specific cytotoxic T lymphocytes.
Babel N, Brestrich G, Gondek LP, Sattler A, Wlodarski MW, Poliak N, Bethke N, Thiel A, Hammer MH, Reinke P and Maciejewski JP.
(2009) J Am Soc Nephrol. 20, 344-52; doi: https://doi.org/10.1681/ASN.2007111225
Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: a single center experience.
Babel N, Gabdrakhmanova L, Juergensen JS, Eibl N, Hoerstrup J, Hammer M, Rosenberger C, Hoeflich C, Frei U, Rohde F, Volk HD and Reinke P.
(2004) Transplantation. 78, 283-5; doi: https://doi.org/
Sex-Associated Differences in Cytomegalovirus Prevention: Prophylactic Strategy is Potentially Associated With a Strong Kidney Function Impairment in Female Renal Transplant Patients.
Blazquez-Navarro A, Dang-Heine C, Bauer C, Wittenbrink N, Wolk K, Sabat R, Witzke O, Westhoff TH, Sawitzki B, Reinke P, Thomusch O, Hugo C, Babel N and Or-Guil M.
(2020) Front Pharmacol. 11, 534681; doi: https://doi.org/534681
Interactions of TTV with BKV, CMV, EBV, and HHV-6A and their impact on post-transplant graft function in kidney transplant recipients.
Rosiewicz KS, Blazquez-Navarro A, Kaliszczyk S, Bauer C, Or-Guil M, Viebahn R, Zgoura P, Reinke P, Roch T, Hugo C, Westhoff T, Thieme C, Stervbo U and Babel N.
(2024) Front Transplant. 3, 1393838; doi: https://doi.org/1393838
High incidence and viral load of HHV-6A in a multi-centre kidney transplant cohort.
Blazquez-Navarro A, Roch T, Wehler P, Kaliszczyk S, Bauer C, Thieme C, Rosiewicz KS, Stervbo U, Anft M, Reinke P, Hugo C, Zgoura P, Viebahn R, Westhoff T, Or-Guil M and Babel N.
(2023) Front Transplant. 2, 1188535; doi: https://doi.org/1188535
In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorder.
Thieme CJ, Schulz M, Wehler P, Anft M, Amini L, Blàzquez-Navarro A, Stervbo U, Hecht J, Nienen M, Stittrich AB, Choi M, Zgoura P, Viebahn R, Schmueck-Henneresse M, Reinke P, Westhoff TH, Roch T and Babel N.
(2022) Kidney Int. 102, 1392-1408; doi: https://doi.org/10.1016/j.kint.2022.08.025
Risk factors for Epstein-Barr virus reactivation after renal transplantation: Results of a large, multi-centre study.
Blazquez-Navarro A, Dang-Heine C, Wehler P, Roch T, Bauer C, Neumann S, Blazquez-Navarro R, Kurchenko A, Wolk K, Sabat R, Westhoff TH, Olek S, Thomusch O, Seitz H, Reinke P, Hugo C, Sawitzki B, Or-Guil M and Babel N.
(2021) Transpl Int. 34, 1680-1688; doi: https://doi.org/10.1111/tri.13982
Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
Zimmermann H, Nitsche M, Pott C, Reinke P, Babel N, Hermann RM, Hauser IA, Hahn D, Ritgen M, Pietschmann C, Klapper W, Anagnostopoulos I, Trappe RU and .
(2021) Ann Hematol. 100, 2043-2050; doi: https://doi.org/10.1007/s00277-021-04548-2
The role of soluble mediators in the clinical course of EBV infection and B cell homeostasis after kidney transplantation.
Bajda S, Blazquez-Navarro A, Samans B, Wehler P, Kaliszczyk S, Amini L, Schmueck-Henneresse M, Witzke O, Dittmer U, Westhoff TH, Viebahn R, Reinke P, Thomusch O, Hugo C, Olek S, Roch T and Babel N.
(2020) Sci Rep. 10, 19594; doi: https://doi.org/19594
BKV, CMV, and EBV Interactions and their Effect on Graft Function One Year Post-Renal Transplantation: Results from a Large Multi-Centre Study.
Blazquez-Navarro A, Dang-Heine C, Wittenbrink N, Bauer C, Wolk K, Sabat R, Westhoff TH, Sawitzki B, Reinke P, Thomusch O, Hugo C, Or-Guil M and Babel N.
(2018) EBioMedicine. 34, 113-121; doi: https://doi.org/10.1016/j.ebiom.2018.07.017
IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: a longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment.
Hinrichs C, Wendland S, Zimmermann H, Eurich D, Neuhaus R, Schlattmann P, Babel N, Riess H, Gärtner B, Anagnostopoulos I, Reinke P and Trappe RU.
(2011) Transpl Int. 24, 892-903; doi: https://doi.org/10.1111/j.1432-2277.2011.01282.x
Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients.
Babel N, Vergopoulos A, Trappe RU, Oertel S, Hammer MH, Karaivanov S, Schneider N, Riess H, Papp-Vary M, Neuhaus R, Gondek LP, Volk HD and Reinke P.
(2007) Transplantation. 84, 387-91; doi: https://doi.org/
Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Trappe R, Riess H, Babel N, Hummel M, Lehmkuhl H, Jonas S, Anagnostopoulos I, Papp-Vary M, Reinke P, Hetzer R, Dörken B and Oertel S.
(2007) Transplantation. 83, 912-8; doi: https://doi.org/
Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
Oertel S, Trappe RU, Zeidler K, Babel N, Reinke P, Hummel M, Jonas S, Papp-Vary M, Subklewe M, Dörken B, Riess H and Gärtner B.
(2006) Ann Hematol. 85, 478-84; doi: https://doi.org/
Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection.
Savoldo B, Huls MH, Liu Z, Okamura T, Volk HD, Reinke P, Sabat R, Babel N, Jones JF, Webster-Cyriaque J, Gee AP, Brenner MK, Heslop HE and Rooney CM.
(2002) Blood. 100, 4059-66; doi: https://doi.org/
Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
Hammer MH, Brestrich G, Mittenzweig A, Roemhild A, Zwinger S, Subklewe M, Beier C, Kurtz A, Babel N, Volk HD and Reinke P.
(2007) J Immunother. 30, 817-24; doi: https://doi.org/
Interactions of TTV with BKV, CMV, EBV, and HHV-6A and their impact on post-transplant graft function in kidney transplant recipients.
Rosiewicz KS, Blazquez-Navarro A, Kaliszczyk S, Bauer C, Or-Guil M, Viebahn R, Zgoura P, Reinke P, Roch T, Hugo C, Westhoff T, Thieme C, Stervbo U and Babel N.
(2024) Front Transplant. 3, 1393838; doi: https://doi.org/1393838
High incidence and viral load of HHV-6A in a multi-centre kidney transplant cohort.
Blazquez-Navarro A, Roch T, Wehler P, Kaliszczyk S, Bauer C, Thieme C, Rosiewicz KS, Stervbo U, Anft M, Reinke P, Hugo C, Zgoura P, Viebahn R, Westhoff T, Or-Guil M and Babel N.
(2023) Front Transplant. 2, 1188535; doi: https://doi.org/1188535
SARS-CoV-2 vaccination improves HBV seroconversion rate through heterological immunity.
Anft M, Paniskaki K, Giglio T, Wellenkötter J, Blazquez-Navarro A, Meister TL, Roch T, Giesecke-Thiel C, Westhoff TH, Stervbo U, Pfaender S, Cinkilic O and Babel N.
(2023) Kidney Int. 103, 223-225; doi: https://doi.org/10.1016/j.kint.2022.10.012
Robust hepatitis B vaccine-reactive T cell responses in failed humoral immunity.
Awad G, Roch T, Stervbo U, Kaliszczyk S, Stittrich A, Hörstrup J, Cinkilic O, Appel H, Natrus L, Gayova L, Seibert F, Bauer F, Westhoff T, Nienen M and Babel N.
(2021) Mol Ther Methods Clin Dev. 21, 288-298; doi: https://doi.org/10.1016/j.omtm.2021.03.012
Generation of HBsAg-reactive T- and B-cells following HBV vaccination in serological non-responders under hemodialysis treatment.
Roch T, Giesecke-Thiel C, Blazquez-Navarro A, Wehler P, Thieme CJ, Juelke K, Grütz G, Hörstrup J, Witzke O, Dittmer U, Stervbo U, Reinke P, Westhoff TH and Babel N.
(2021) Eur J Immunol. 51, 1278-1281; doi: https://doi.org/10.1002/eji.202048756
